Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32. The acquisition is intended to strengthen Ginkgo’s Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services. Ginkgo does not have a product portfolio or drug pipeline. Instead, Ginkgo provides R&D services to customers who are looking to innovate across industries, including many world-class partners in biopharma.
Read the full article: Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers //
Source: https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-patch-biosciences-expanding-suite-of-genetic-medicine-capabilities-available-to-customers-302073671.html